ETON
Eton Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$41.07-2.95%
Price as of Jul 20, 2026
ETON financials
Eton Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M |
| Cost of revenue | $37.2M | $15.6M | $10.6M | $6.9M |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M |
| Operating expenses | $42.7M | $26.0M | $22.3M | $22.6M |
| Operating income | $72.0K | -$2.6M | -$1.2M | -$8.3M |
| Net income | -$4.6M | -$3.8M | -$936.0K | -$9.0M |
| EBITDA | $4.3M | -$657.0K | $212.0K | -$7.2M |
| Basic EPS | $-0.17 | $-0.15 | $-0.04 | $-0.36 |
| Diluted EPS | $-0.17 | $-0.15 | $-0.04 | $-0.36 |
| Balance sheet | ||||
| Cash & equivalents | $25.9M | $14.9M | $21.4M | $16.3M |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M |
| Stockholders’ equity | $26.2M | $24.4M | $15.5M | $13.1M |
| Total debt | $31.0M | $30.0M | $5.4M | $6.5M |
| Net debt | $5.1M | $15.1M | -$16.0M | -$9.8M |
| Cash flow | ||||
| Operating cash flow | $10.5M | $969.0K | $6.8M | $4.8M |
| Capital expenditure | -$333.0K | -$26.0K | -$775.0K | -$2.8M |
| Free cash flow | $10.2M | $943.0K | $6.0M | $2.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |